To better understand the implications of the rate of prostate speci®c antigen (PSA) changes in prostate carcinoma.
To better understand the implications of the rate of prostate speci®c antigen (PSA) changes in prostate carcinoma.
Method
We retrospectively calculated PSA doubling times prior to surgery in 63 patients with prostate carcinoma. The calculated values were compared with ®nal pathologic ®ndings and with rates of PSA failure after surgery.
Results
PSA values increased during the period of observation in 82.5% of the patients, whereas 17.5% had levels that remained stable. The median calculated PSA doubling time in those with increasing levels was 25.9 months, with doubling times 24 months observed in 36.5% of the patients. Stage pT3 disease was more common in patients with PSA doubling times of 36 months than in those with doubling times b 36 months (P 0.04). Biochemical failure was more common in patients with rapid PSA doubling times (P 0.03).
Conclusion
The calculated PSA doubling time prior to radical surgery is signi®cantly associated with the ®nal pathologic ®nd-ings. Early PSA failure is more common in patients with rapid PSA doubling times prior to radical surgery.
